S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
Cintas: A Quality Buy and Hold Forever Stock at Any Price
The single greatest medical breakthrough of all time? (Ad)
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
3 Household Names With RSIs That Scream Oversold
66,000% upside on tiny biotech? (Ad)
The Odds Are High Costco Will Declare a Special Dividend Soon 
Stock market today: Global shares mostly fall over China worries
66,000% upside on tiny biotech? (Ad)
This Little Known Automaker May Save Your Life and Your Portfolio
How You Can Reverse Engineer Michael Burry's Latest Buy
S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
Cintas: A Quality Buy and Hold Forever Stock at Any Price
The single greatest medical breakthrough of all time? (Ad)
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
3 Household Names With RSIs That Scream Oversold
66,000% upside on tiny biotech? (Ad)
The Odds Are High Costco Will Declare a Special Dividend Soon 
Stock market today: Global shares mostly fall over China worries
66,000% upside on tiny biotech? (Ad)
This Little Known Automaker May Save Your Life and Your Portfolio
How You Can Reverse Engineer Michael Burry's Latest Buy
S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
Cintas: A Quality Buy and Hold Forever Stock at Any Price
The single greatest medical breakthrough of all time? (Ad)
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
3 Household Names With RSIs That Scream Oversold
66,000% upside on tiny biotech? (Ad)
The Odds Are High Costco Will Declare a Special Dividend Soon 
Stock market today: Global shares mostly fall over China worries
66,000% upside on tiny biotech? (Ad)
This Little Known Automaker May Save Your Life and Your Portfolio
How You Can Reverse Engineer Michael Burry's Latest Buy
S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
Cintas: A Quality Buy and Hold Forever Stock at Any Price
The single greatest medical breakthrough of all time? (Ad)
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
3 Household Names With RSIs That Scream Oversold
66,000% upside on tiny biotech? (Ad)
The Odds Are High Costco Will Declare a Special Dividend Soon 
Stock market today: Global shares mostly fall over China worries
66,000% upside on tiny biotech? (Ad)
This Little Known Automaker May Save Your Life and Your Portfolio
How You Can Reverse Engineer Michael Burry's Latest Buy

Penumbra (PEN) Stock Forecast, Price & News

$240.75
-4.86 (-1.98%)
(As of 09/27/2023 ET)
Compare
Today's Range
$239.99
$250.15
50-Day Range
$245.61
$308.03
52-Week Range
$144.76
$348.67
Volume
247,041 shs
Average Volume
353,598 shs
Market Capitalization
$9.25 billion
P/E Ratio
325.34
Dividend Yield
N/A
Price Target
$324.38

Penumbra MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.85 Rating Score
Upside/​Downside
34.7% Upside
$324.38 Price Target
Short Interest
Bearish
5.83% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.40
Upright™ Environmental Score
News Sentiment
0.70mentions of Penumbra in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$9.33 M Sold Last Quarter
Proj. Earnings Growth
56.65%
From $1.73 to $2.71 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.65 out of 5 stars

Medical Sector

111th out of 976 stocks

Surgical & Medical Instruments Industry

20th out of 98 stocks


PEN stock logo

About Penumbra (NYSE:PEN) Stock

Penumbra, Inc., together with its subsidiairies, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, SENDit, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System, Lightning, and CAT RX brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and POD (Penumbra Occlusion Device) brand, as well as immersive 3D computer-based technology platform under the Real Immersive System brand; and a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and Packing Coil LP brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

PEN Price History

PEN Stock News Headlines

BTIG Sticks to Their Buy Rating for Penumbra (PEN)
Holding NVDA? Read This Now
NVDA is likely not the best buy for A.I. investors. 50-year Wall Street veteran Marc Chaikin reveals what to buy instead. Learn more here.
Penumbra's (PEN) Overweight Rating Reaffirmed at Piper Sandler
Buy These 3 Low-Beta Stocks to Counter Market Volatility
Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
Analyst Expectations for Penumbra's Future
Penumbra (PEN) Gets a Buy from BTIG
Check Out What Whales Are Doing With PEN
RBC Capital Sticks to Its Buy Rating for Penumbra (PEN)
Q2 2023 Penumbra Inc Earnings Call
Penumbra: Q2 Earnings Snapshot
See More Headlines
Receive PEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Penumbra and its competitors with MarketBeat's FREE daily newsletter.

PEN Company Calendar

Last Earnings
8/01/2023
Today
9/28/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Employees
3,900
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$324.38
High Stock Price Forecast
$390.00
Low Stock Price Forecast
$230.00
Forecasted Upside/Downside
+34.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.85
Research Coverage
13 Analysts

Profitability

Net Income
$-2,000,000.00
Pretax Margin
4.09%

Debt

Sales & Book Value

Annual Sales
$937.79 million
Cash Flow
$0.79 per share
Book Value
$26.30 per share

Miscellaneous

Free Float
36,400,000
Market Cap
$9.25 billion
Optionable
Optionable
Beta
0.54
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Adam ElsesserMr. Adam Elsesser (Age 61)
    Co-Founder, Chairman, Pres & CEO
    Comp: $601.62k
  • Dr. Arani Bose M.D. (Age 61)
    Co-Founder & Director
    Comp: $37.5k
  • Ms. Maggie S. Yuen (Age 51)
    Chief Financial Officer
    Comp: $660.98k
  • Mr. Lambert Shiu (Age 43)
    Chief Accounting Officer
    Comp: $539.15k
  • Ms. Johanna RobertsMs. Johanna Roberts (Age 51)
    Exec. VP, Gen. Counsel & Sec.
    Comp: $655.75k
  • Ms. Lynn Rothman (Age 62)
    Exec. VP & Chief Bus. Officer
  • Mr. Ben Sorci
    Exec. VP of Operations
  • Mr. Pankaj Tiwari
    Exec. VP & Chief Information Officer
  • Ms. Jee Hamlyn-Harris
    Investor Relations Officer
  • Mr. Ben Tompkins
    Exec. VP of Devel.













PEN Stock - Frequently Asked Questions

Should I buy or sell Penumbra stock right now?

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Penumbra in the last twelve months. There are currently 2 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" PEN shares.
View PEN analyst ratings
or view top-rated stocks.

What is Penumbra's stock price forecast for 2023?

13 brokers have issued twelve-month price targets for Penumbra's shares. Their PEN share price forecasts range from $230.00 to $390.00. On average, they predict the company's share price to reach $324.38 in the next year. This suggests a possible upside of 34.7% from the stock's current price.
View analysts price targets for PEN
or view top-rated stocks among Wall Street analysts.

How have PEN shares performed in 2023?

Penumbra's stock was trading at $222.46 on January 1st, 2023. Since then, PEN shares have increased by 8.2% and is now trading at $240.75.
View the best growth stocks for 2023 here
.

When is Penumbra's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our PEN earnings forecast
.

How were Penumbra's earnings last quarter?

Penumbra, Inc. (NYSE:PEN) announced its quarterly earnings data on Tuesday, August, 1st. The company reported $0.43 EPS for the quarter, beating analysts' consensus estimates of $0.28 by $0.15. The firm earned $261.50 million during the quarter, compared to the consensus estimate of $253.59 million. Penumbra had a trailing twelve-month return on equity of 3.16% and a net margin of 3.11%. The company's revenue for the quarter was up 25.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.01 EPS.

What guidance has Penumbra issued on next quarter's earnings?

Penumbra updated its FY 2023 earnings guidance on Tuesday, August, 1st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.05 billion-$1.07 billion, compared to the consensus revenue estimate of $1.05 billion.

What is Adam Elsesser's approval rating as Penumbra's CEO?

57 employees have rated Penumbra Chief Executive Officer Adam Elsesser on Glassdoor.com. Adam Elsesser has an approval rating of 88% among the company's employees.

What other stocks do shareholders of Penumbra own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Penumbra investors own include NVIDIA (NVDA), Intuitive Surgical (ISRG), AbbVie (ABBV), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Netflix (NFLX), UnitedHealth Group (UNH), Boeing (BA) and DexCom (DXCM).

What is Penumbra's stock symbol?

Penumbra trades on the New York Stock Exchange (NYSE) under the ticker symbol "PEN."

Who are Penumbra's major shareholders?

Penumbra's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (10.73%), Capital Research Global Investors (6.76%), State Street Corp (2.76%), Clearbridge Investments LLC (2.36%), Baillie Gifford & Co. (1.82%) and William Blair Investment Management LLC (1.74%). Insiders that own company stock include Adam Elsesser, Arani Bose, Bridget O'rourke, Don W Kassing, Don W Kassing, Harpreet Grewal, James Robert Pray, Johanna Roberts, Surbhi Sarna and Thomas Wilder.
View institutional ownership trends
.

How do I buy shares of Penumbra?

Shares of PEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Penumbra's stock price today?

One share of PEN stock can currently be purchased for approximately $240.75.

How much money does Penumbra make?

Penumbra (NYSE:PEN) has a market capitalization of $9.25 billion and generates $937.79 million in revenue each year. The company earns $-2,000,000.00 in net income (profit) each year or $0.74 on an earnings per share basis.

How many employees does Penumbra have?

The company employs 3,900 workers across the globe.

How can I contact Penumbra?

Penumbra's mailing address is One Penumbra Place, Alameda CA, 94502. The official website for the company is www.penumbrainc.com. The company can be reached via phone at (510) 748-3200, via email at investors@penumbrainc.com, or via fax at 510-748-3232.

This page (NYSE:PEN) was last updated on 9/28/2023 by MarketBeat.com Staff

My Account -